Follow us on Twitter
twitter icon@FreshPatents


Receptor patents

      

This page is updated frequently with new Receptor-related patent applications.




 Secondary battery patent thumbnailSecondary battery
A secondary battery in which the difference between the voltage at the time of discharging and the voltage at the time of charging is small, ensuring good energy efficiency, and the charge/discharge life is long. Therefore, in order to attain the above-described object, a secondary battery containing a positive electrode, a negative electrode, and an electrolytic solution, wherein at least one of the positive electrode and the negative electrode contains, as the active material, at least one selected from the group consisting of a metal ion-containing fluoride, a metal oxide, a metal sulfide, a metal nitride, and a metal phosphide; the electrolytic solution contains an anion receptor; and the anion receptor forms a salt or a complex with an anion contained in the active material, thereby enabling the active material to dissolve in the electrolytic solution..
Honda Motor Co., Ltd.


 Materials and methods for diagnosing and predicting the course of prostate cancer patent thumbnailMaterials and methods for diagnosing and predicting the course of prostate cancer
Expression of forkhead-box protein a1 (foxa1), a transcription factor important for the normal development of the prostate gland is thought to be controlled by steroid hormones and gata-3. Expression of foxa1, gata-3 and androgen receptor (ar) was retrospectively analyzed by immunohistochemistry (ihc) in a series of 80 primary tumors and 28 metastatic prostate cancers including 15 matched paired samples.
Indiana University Research And Technology Corporation


 Tlr-4 based electrochemical biosensor patent thumbnailTlr-4 based electrochemical biosensor
The present invention relates to an apparatus comprising tlr-4 based electrochemical biosensor and a method for using the same to detect the presence of gram-negative bacteria or lipopolysaccharide in a sample. In one particular embodiment, the apparatus comprises an electric conducting solid substrate surface having a monolayer of a mixture of linkers each of which has a first functional group that is attached to the surface of said electric conducting solid substrate.
Uti Limited Partnership


 Ddr2 mutations in squamous cell lung cancer patent thumbnailDdr2 mutations in squamous cell lung cancer
Methods for treating patients with squamous cell lung cancer, including detecting the presence of mutations in the discoidin domain receptor 2 (ddr2) gene.. .
Dana-farber Cancer Institute, Inc.


 Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients patent thumbnailMethods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (egfr) inhibitor. The biomarkers of the present invention include detection of egfr and her 2 gene amplification and polysomy, egfr protein expression, egfr mutations, phosphorylated akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the egfr gene.
The Regents Of The University Of Colorado, A Body Corporate


 Novel  screening for prostate cancer patent thumbnailNovel screening for prostate cancer
The invention relates to a method for the in vitro diagnosis of prostate cancer in a patient, characterised in that it comprises a step of measuring the expression level of the gene of the cation-independent mannose-6-phosphate receptor (ci-m6pr) in a sample of prostate tissue of the patient, the determination of overexpression of said ci-m6pr gene indicating the presence of prostate cancer in said patient.. .
Centre Hospitalier Universitaire De Toulouse


 Methods and compositions for the treatment of post-traumatic stress disorder patent thumbnailMethods and compositions for the treatment of post-traumatic stress disorder
Methods and compositions are disclosed to treat neuropsychiatric disorders post-traumatic stress disorder (ptsd). In particular, described herein are angiotensin receptor blockers (arbs), and in particular the combination of one or more arb (such as telmisartan) and an agent that enhances the delivery of the arb across the blood-brain barrier (such as minocycline).

 Production of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection patent thumbnailProduction of engineered t-cells by sleeping beauty transposon coupled with methotrexate selection
Aspects of the invention described herein include methods of treating, inhibiting, ameliorating and/or eliminating a virus or cancer cells in a subject utilizing genetically engineered human t-cells having receptors for a molecule presented by the virus or the cancer cells, wherein the genetically engineered t cells are isolated utilizing a two-stage mtx selection that employs increasing concentrations of mtx.. .
Seattle Children's Hospital (dba Seattle Children' Research Institute)


 Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof patent thumbnailAnti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
The present disclosure provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (il1 rap) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘can04’ to human il1 rap. The disclosure further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of il-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma..
Cantargia Ab


 Anti-cd123 antibodies and conjugates and derivatives thereof patent thumbnailAnti-cd123 antibodies and conjugates and derivatives thereof
The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to cd123 antigen (the α chain of the interleukine 3 receptor, or il-3rα). The present invention also relates to methods of using such cd123-binding molecules for diagnosing and treating diseases, such as b-cell malignancies..
Immunogen, Inc.


Methods of improving or accelerating physical recovery after surgery for hip fracture

The disclosure relates to uses and regimens for accelerating/improving physical recovery in a patient with disuse atrophy triggered by reduced mobility due to a hip fracture and consequent major surgery, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an actrii receptor binding molecule, an actrii receptor antibody, such as the bimagrumab antibody.. .
Novartis Ag

Pdgf receptor beta binding polypeptides

The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human pdgfrβ) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides.
X-body, Inc.

Immunoglobulins binding human vgamma9 vdelta2 t cell receptors

The invention is in the field of medicine and relates to immunology, and relates in particular to human vγ9vδ2 t cell receptor binding immunoglobulin molecules. Human vγ9vδ2 t cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human vγ9vδ2 t cells, wherein human vγ9vδ2 t cells may be modulated..
Stichting Vumc

Multimeric fc proteins

The invention relates to multimeric proteins which bind to human fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune and other disorders..
Ucb Biopharma Sprl

Use of inhibitors of leukotriene b4 receptor blt2 for treating asthma

The present invention relates to the use of inhibitors of leukotriene b4 receptor blt2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising blt2 inhibitors and a method for treating asthma using blt2 inhibitors..
Korea University Research & Business Foundation

Human antibodies to human delta like ligand 4

The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hdll4) and blocks hdll4 binding to a notch receptor. The anti-hdll4 antibody or fragment thereof of the present invention have a high affinity with the kd of 500 pm or less, as measured by surface plasmon resonance..
Regeneron Pharmaceuticals, Inc.

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Isolated t cell receptors and methods of use therefor

Provided are isolated tcrs, tcr-like molecules, and portions thereof that bind to phosphopeptide-hla-a2 complexes. The isolated tcrs, tcr-like molecules, or portions are optionally soluble tcrs, tcr-like molecules, or portions.
University Of Virginia Patent Foundation

Murine anti-ny-eso-1 t cell receptors

The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Compounds that bind to the erythropoietin receptor

The present invention provides mimetics of erythropoietin that bind to the erythropoietin receptor and that are suitable for use in pharmaceutical compositions. The present invention also provides methods of treatment using the mimetics of erythropoietin as well as methods of making the mimetics of erythropoietin..
Epodose Llc

Chimeric fibroblast growth factor 21 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf21 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses

A fusion protein for use as an immunogen enhancer for enhancing antigen-specific t cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (apc)-binding domain or a cd91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen of a pathogen, wherein the apc-binding domain or the cd91 receptor-binding domain is located at the n-terminus of the fusion protein, and the antigen of the pathogen is located at the c-terminus of the protein transduction domain.
Thevax Genetics Vaccine Co., Ltd.

(+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof

The present invention provides (+)-morphinans comprising toll-like receptor 9 (tlr9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain..
Mallinckrodt Llc

Novel chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof

The present invention relates to novel compounds of formula i and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using n-sp3 protective groups.

Novel substituted imidazoquinolines

Imidazoquinolines of formula i that contain substituted amine or amide functionality at 1-position and that are effective as toll like receptor 7 activators are disclosed. These compounds are useful as anticancer agents..
4sc Ag

Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds

The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides tlr7 agonists and tlr7/tlr8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof.
The University Of Kansas

Nk 1 antagonists

Or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by nk1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.. .

2-substituted-5-hydroxy-4h-chromen-4-ones as novel ligands for the serotonin receptor 2b (5-ht2b)

A family of compounds which function as selective ligands for the serotonin receptor 2b (5-ht2b) is identified. Some of the compounds are synthetic non-natural ligands which have a relatively strong interaction with 5-ht2b compared to naturally occurring compounds (some of which are identified for the first time herein as ligands for 5-ht2b).
Virginia Commonwealth University

5-ht2b antagonists

And related methods for treating a person having a disorder characterized by undesirable 5-ht2b receptor signaling, such as migraine, irritable bowel syndrome (ibs), pulmonary arterial hypertension (pah), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (gi) tract disorders.. .

Selective androgen receptor degrader (sard) ligands and methods of use thereof

This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (sard) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other ar-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, kennedy's disease, amyotrophic lateral sclerosis (als), abdominal aortic aneurysm (aaa), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (ar-fl) including pathogenic and/or resistance mutations, ar-splice variants (ar-sv), and pathogenic polyglutamine (polyq) polymorphisms of ar in a subject.. .
University Of Tennessee Research Foundation

Methods of transferring pillars from pillar delivery films

Pillar delivery films for vacuum insulated glass units are disclosed. The delivery films include a support film or pocket tape, a sacrificial material on the support film, and a plurality of pillars.
3m Innovative Properties Company

Vaccine composition

An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (tlr4) agonist, a toll-like receptor 2/6 (tlr2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof..
Nitto Denko Corporation

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. .
Nps Pharmaceuticals, Inc.

Liquid formulation of a fusion protein comprising tnfr and fc region

The present invention relates to a liquid formulation comprising a tnfr-fc fusion protein and a stabilizer, in which the fusion protein comprises tnfr (tumor necrosis factor receptor) or a fragment thereof and an immunoglobulin fc region, and the stabilizer comprises one or more amino acids selected from the group consisting of proline and histidine, a buffer solution, and an isotonic agent containing sodium chloride (nacl) and sucrose, and a preparation method of the liquid formulation. The liquid formulation according to the present invention provides excellent storage stability because long-term storage of tnfr-fc fusion protein (etanercept) is possible and particular storage conditions are not needed.
Ares Trading S.a.

Immunotherapy of cancer using genetically engineered gd2-specific t cells

The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside gd2 antigen. In specific embodiment, t cells having a chimeric receptor that targets gd2 is employed.
Baylor College Of Medicine

Methods of treating coronavirus infection

The present invention provides methods for treating a coronavirus infection. For example, treatment may be effected by administering a neurotransmitter inhibitor, a signaling kinase inhibitor, an estrogen receptor inhibitor, a dna metabolism inhibitor or an anti-parasitic agent.
United States Government As Represented By The Secretary, Department Of Health And Human Services

Methods and compositions for treatment of drug addiction

Methods of reducing ampa/nmda ratio in d1-type medium spiny neurons (msn) and/or reducing development of behavioural sensitization or suppressing drug induced behavioural sensitization in a subject, optionally a subject that is afflicted with an addiction, the method comprising administering to the subject in need thereof an effective amount of a toll-like receptor 4 (tlr4) agonist or a composition comprising said tlr4 agonist, preferably wherein the tlr4 agonist is a monophosphoryl lipid a (mpla).. .
The Royal Institution For The Advancement Of Learning / Mcgill University

New compounds as positive allosteric modulators for erythropoietin and erythropoietin receptor to treat erythropoietin deficiency diseases

Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds..

Methods and compositions for treatment of peripheral neuropathies

A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a muscarinic receptor antagonist, and combinations thereof, and a pharmacologically acceptable carrier and/or an excipient.
University Of Manitoba

Novel compounds

Corresponding manufacture processes, pharmaceutical formulations containing and uses of the aforementioned compound in therapy, particularly in treatment of diseases where under-activation of the hm74a receptor contributes to the disease or where activation of the receptor will be beneficial.. .

Abl1 inhibitor for treating and preventing ocular neovascularisation

The present invention relates to an abelson murine leukaemia viral oncogene homolog 1 (abl1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an abl1 inhibitor as a complementary therapy with vegf or vegf receptor inhibitor treatment and provides pharmaceutical compos itions and kits comprising one or both inhibitors..
Ucl Business Plc

Piperidinone carboxamide azaindane cgrp receptor antagonists

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists ofcgrp receptors and useful in the treatment or prevention of diseases in which the cgrp is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.

Compositions and methods for prophylaxis and treatment of addictions

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (pparγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a pparγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse.
Omeros Corporation

Antitussive compositions and methods

Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the α7 nachr subtype, and methods for suppressing cough.. .
Attenua, Inc.

Compositions and methods for treating opioid receptor associated diseases

The invention relates to dezocine compositions and uses thereof. Specifically, the invention relates to dezocine compositions, including nano-dezocine compositions and methods for preventing or treating opioid receptor associated diseases, including neuropathic pain; addiction, such as opioid or cocaine addiction; and depression..
The Trustees Of The University Of Pennsylvania

Solid dispersion comprising an orexin receptor antagonist

A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.. .
Sandoz Ag

Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases

The current invention provides a new and original method for treatment of ocular inflammatory diseases. More particularly, the present invention relates a mineralocorticoid receptor agonist for use in the treatment of an ocular inflammatory disease..
UniversitÉ Paris Descartes

Hat with receptor

A receptor that can be associated with an aperture through the wall of a hat and receive items such as the stems of a pair of sunglasses. The receptor is generally attached only at the aperture..





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.7035

file did exist - file did put2726

3 - 1 - 60